Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Matthew Henn, PhD
EVP, Chief Scientific Officer
Seres Therapeutics, Cambridge, MA
Poster(s):
(653) Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent
Clostridioides difficile
Infection (rCDI)
Thursday, October 12, 2023
12:15 PM – 1:30 PM
US ET
(655) Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent
Clostridioides difficile
Infection
Thursday, October 12, 2023
12:15 PM – 1:30 PM
US ET
(2156) The Rational Design of SER-147: a Cultivated Microbial Consortium to Restore Colonization Resistance and Mitigate Infection in Chronic Liver Disease
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
